An observational study in Behcet Disease and Vascular Affection, sponsored by Assiut University. Not yet recruiting. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Behcet Syndrome by Assiut University — 6 open to participants now, 6 under way, none of them phase 3. Behcet Syndrome · Assiut University.
Among the 18 studies in Behcet Syndrome by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2024, is one of 14 observational ones, and was the 11th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →6 of the 18 studies in Behcet Syndrome by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 18+ · Healthy volunteers
Assiut University
Ages 20–45
Assiut University
Ages 19–60 · Healthy volunteers
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 20 Years to 45 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Median enrollment 35 across the 4 interventional studies, 77 across the 14 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Behcet Syndrome by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07845162Assiut UniversitySerum EBI-3 Protein Levels in Behçet's Disease | 2027-09-26 |
| NCT07803198Assiut UniversityAsprosin in Behect Patients | 2027-09-30 |
| NCT07157189Assiut UniversityClinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Behcet Syndrome by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To measure the level of serum elafin in patients with BD. To assess the relation between serum elafin levels and disease activity. To evaluate the vascular complications in BD and determine their relationship with disease activity.
To assess the correlation between serum elafin and vascular affection and their relation with disease activity.
Behçet's disease (BD) is a chronic, multisystemic, inflammatory disease characterized by recurrent oral and genital ulcers and multiple systemic involvements. Elafin is a serine protease inhibitor produced mainly by epithelial cells. Its expression is upregulated by proinflammatory cytokines such as IL-1β and TNF-α that are potent stimulants of neutrophil activation, it counteracts the destructive effects of neutrophil elastase .Interestingly, previous reports documented the role of serum elafin in the pathogenesis of BD.In fact, vascular complications may be one of the earliest manifestations leading to the diagnosis of BD. There is no reliable tool to identify vascular wall inflammation in BD, except for detecting intravascular thrombosis with ultrasonography (US). Previous studies investigated arterial vessel wall thickness with US (mostly in carotid arteries) in BD . Venous wall inflammation presents with deep vein thrombosis and superficial thrombophlebitis . It was stated that lower extremity vein wall thickness (VWTs)was increased in BD patients independently of vascular activity and important in the diagnosis . However, studies in the literature evaluated only lower extremity VWTs, whereas the relationship of VWT with disease activity has not been emphasized .
Patients diagnosed as BD. Age of all participants (20-45) years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients diagnosed as BD. Age of all participants (20-45) years.
Exclusion Criteria:
Age \<20 or >45 years. Other diseases. Cardiovascular diseases (heart failure, myocardial ischemia). Possible related risk factors (e.g. diabetes, dyslipidemia, smoking). chronic conditions (e.g. chronic kidney disease, , autoimmune diseases).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: doppler ultrasound
Device: doppler ultrasound
doppler US
Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.
Measuring the level of serum Elafin in patients with BD in comparison to healthy participants.
Time frame: within one year
No study locations are listed for this record.
Start is estimated for Mar 2024; primary completion for Mar 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.